Format

Send to

Choose Destination
Pharmacol Ther. 2019 Jun 6. pii: S0163-7258(19)30109-3. doi: 10.1016/j.pharmthera.2019.06.002. [Epub ahead of print]

Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy.

Author information

1
Department of Neurology, The Chaim Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, 6997801 Tel Aviv, Israel.
2
Department of Neurology, The Chaim Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
3
Department of Neurology, The Chaim Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, 6997801 Tel Aviv, Israel.; Talpiot Medical Leadership Program - The Chaim Sheba Medical Center at Tel HaShomer, 52621, Ramat Gan, Israel.. Electronic address: Nicola.maggio@sheba.health.gov.il.

Abstract

Interest in cannabis and its related cannabinoids THC and CBD for use as anti-convulsant therapy has been progressively increasing. While the destigmatization of cannabis and cannabis related research have progressed in the last few decades, there are still many questions that remain answered. This review seeks to summarize the progress made in cannabis research in the past four decades and to identify possible directions for future research that are critical for the development of cannabinoid-based therapy in epilepsy.

KEYWORDS:

(9)THC; Cannabidiol; Cannabis; Epilepsy; Hippocampus; Therapy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center